Dr. Enrique Grande, head of the Medical Oncology Service at MD Anderson Cancer Center Madrid, has been appointed to the Advisory Committee of the European Society of Neuroendocrine Tumors (ENETS).
Neuroendocrine tumors (NETs), which affect the glands or the neuroendocrine system, are rare types of cancers that are quite unknown among public. It is estimated that they affect between six and seven people per 100,000 inhabitants, with about 4,000 new patients being diagnosed annually. So, that this type of patients be treated in reference centers with experience, by multidisciplinary teams with experience in the management of these tumors, is of vital importance to correctly control the disease. These tumors are very diverse due to the composition of their cells, where they grow and the symptoms they produce.
Based on this diversity, Dr. Enrique Grande explains that "it is very difficult to combine experience. Therefore, it is very good news that a Spanish doctor will be part of the committee of experts at a European level, who are in charge of research into neuroendocrine tumors at an international level ", says Dr. Grande. "It is an honor and a great responsibility for me to be part of this advisory committee. It is not only recognition at a personal level, but at a general level in that oncology in Spain has nothing has to envy that of surrounding countries”, said Dr. Grande.
At present, Dr. Grande is also a member of the board of directors of the Spanish Group of Orphan and Infrequent Tumors (GETHI), an institution of which he is a founding partner, and of the Spanish Group of Neuroendocrine Tumors (GETNE). Work he combines with an advisory role in the Spanish Agency of Medicine (Aemps) and his participation as an active member in the Spanish Group of Genitourinary Tumors (SOGUG), where he collaborates with the working committee for the management of renal tumors, and with the Stem Cell Study Group in Oncology (GESTO), where he serves as scientific secretary.